Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients
Maria‐Christina Kyrtsonis(National and Kapodistrian University of Athens), Gerassimos A. Pangalis(Athens Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Flora Kontopidou(National and Kapodistrian University of Athens), K. Konstantopoulos(National and Kapodistrian University of Athens), Marina P. Siakantaris(National and Kapodistrian University of Athens), M. Angelopoulou(National and Kapodistrian University of Athens), George Vaiopoulos, Maria Dimopoulou(National and Kapodistrian University of Athens), T. Vassilakopoulos(National and Kapodistrian University of Athens), Despina A. Gribabis(National and Kapodistrian University of Athens), P Fessas, Christos Kittas(National and Kapodistrian University of Athens)
Cited by 87
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859